• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Molecular remission uncoupled with complete haematological response in polycythaemia vera treatment with ropeginterferon alfa-2b.

作者信息

Suo Shanshan, Fu Rong Feng, Qin Albert, Shao Zonghong, Bai Jie, Zhou Hu, Xu Na, Chen Suning, Zuo Xuelan, Du Xin, Duan Minghui, Wang Li, Li Pei, Zhang Xuhan, Zhang Sujiang, Wu Daoxiang, Zhang Jingjing, Xiao Zhijian, Zhang Lei, Jin Jie

机构信息

Department of Haematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.

State Key Laboratory of Experimental Haematology, National Clinical Research Center for Blood Diseases, Institute of Haematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.

出版信息

Br J Haematol. 2024 Dec;205(6):2510-2514. doi: 10.1111/bjh.19846. Epub 2024 Oct 27.

DOI:10.1111/bjh.19846
PMID:39462216
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11637735/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/955e/11637735/fcba7c950dda/BJH-205-2510-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/955e/11637735/fcba7c950dda/BJH-205-2510-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/955e/11637735/fcba7c950dda/BJH-205-2510-g001.jpg

相似文献

1
Molecular remission uncoupled with complete haematological response in polycythaemia vera treatment with ropeginterferon alfa-2b.在真性红细胞增多症患者接受聚乙二醇干扰素α-2b治疗过程中，分子学缓解与完全血液学缓解未同时出现。
Br J Haematol. 2024 Dec;205(6):2510-2514. doi: 10.1111/bjh.19846. Epub 2024 Oct 27.
2
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.聚乙二醇干扰素α-2b对比真性红细胞增多症标准疗法（PROUD-PV和CONTINUATION-PV）：一项随机、非劣效性3期试验及其扩展研究。
Lancet Haematol. 2020 Mar;7(3):e196-e208. doi: 10.1016/S2352-3026(19)30236-4. Epub 2020 Jan 31.
3
Exposure-efficacy and exposure-safety analyses of ropeginterferon alfa-2b treatment in patients with polycythaemia vera.聚乙二醇干扰素α-2b治疗真性红细胞增多症患者的暴露-疗效和暴露-安全性分析。
Br J Clin Pharmacol. 2024 Jun;90(6):1493-1502. doi: 10.1111/bcp.16043. Epub 2024 Mar 19.
4
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial.罗哌戈汀干扰素 α-2b 与放血疗法治疗低危真性红细胞增多症患者（Low-PV 研究）：一项多中心、随机 2 期临床试验。
Lancet Haematol. 2021 Mar;8(3):e175-e184. doi: 10.1016/S2352-3026(20)30373-2. Epub 2021 Jan 18.
5
Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study.罗特西普干扰素α-2b 在日本真性红细胞增多症患者中的疗效和安全性：一项开放标签、单臂、2 期研究。
Int J Hematol. 2022 Aug;116(2):215-227. doi: 10.1007/s12185-022-03341-9. Epub 2022 Apr 16.
6
A pharmacokinetic evaluation of ropeginterferon alfa-2b in the treatment of polycythemia vera.罗特西普干扰素 α-2b 治疗真性红细胞增多症的药代动力学评价。
Expert Opin Drug Metab Toxicol. 2021 Jan;17(1):3-7. doi: 10.1080/17425255.2021.1839050. Epub 2020 Oct 29.
7
Cost-effectiveness of ropeginterferon alfa-2b-njft for the treatment of polycythemia vera.罗特西普那非治疗真性红细胞增多症的成本效果分析。
J Comp Eff Res. 2023 Sep;12(9):e230066. doi: 10.57264/cer-2023-0066. Epub 2023 Aug 2.
8
Effectiveness of Ropeginterferon Alfa-2B in High-Risk Patients with Philadelphia Chromosome Negative Myeloproliferative Neoplasms- Evaluation of Clinicohaematologic Response, and Safety Profile: Single Centre Experience.罗特西普治疗费城染色体阴性骨髓增殖性肿瘤高危患者的疗效-临床血液学反应和安全性评估：单中心经验。
Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2023 Dec 18;44(3):57-62. doi: 10.2478/prilozi-2023-0047. Print 2023 Dec 1.
9
A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera.聚乙二醇干扰素α-2b的一种新给药方案高效且耐受性良好：一项针对中国真性红细胞增多症患者的2期研究结果
Exp Hematol Oncol. 2023 Jun 21;12(1):55. doi: 10.1186/s40164-023-00415-0.
10
Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera.聚乙二醇干扰素α-2b，一种新型的干扰素α-2b，在真性红细胞增多症患者中诱导出高缓解率且毒性低。
Blood. 2015 Oct 8;126(15):1762-9. doi: 10.1182/blood-2015-04-637280. Epub 2015 Aug 10.

引用本文的文献

1
Highlights from MPN Asia 2025: Advances in Molecular Pathogenesis and Therapeutic Strategies in Myeloproliferative Neoplasms.2025年亚洲骨髓增殖性肿瘤大会亮点：骨髓增殖性肿瘤分子发病机制与治疗策略的进展
Curr Hematol Malig Rep. 2025 Jul 12;20(1):9. doi: 10.1007/s11899-025-00752-3.
2
A pharmacovigilance study of adverse events associated with polycythemia vera treatments using the FDA Adverse Event Reporting System (FAERS) database.一项利用美国食品药品监督管理局不良事件报告系统（FAERS）数据库对真性红细胞增多症治疗相关不良事件进行的药物警戒研究。
Ann Hematol. 2025 Jul 10. doi: 10.1007/s00277-025-06480-1.
3
A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia in the US and Canada: EXCEED-ET trial.

本文引用的文献

1
Mechanism of Action of Ropeginterferon Alfa-2b in Polycythemia Vera Treatment.聚乙二醇干扰素α-2b治疗真性红细胞增多症的作用机制
Clin Ther. 2024 May;46(5):439-440. doi: 10.1016/j.clinthera.2024.03.005. Epub 2024 May 1.
2
Effective Management of Polycythemia Vera With Ropeginterferon Alfa-2b Treatment.用聚乙二醇干扰素α-2b治疗有效管理真性红细胞增多症
J Hematol. 2024 Apr;13(1-2):12-22. doi: 10.14740/jh1245. Epub 2024 Apr 9.
3
Exposure-efficacy and exposure-safety analyses of ropeginterferon alfa-2b treatment in patients with polycythaemia vera.
一项在美国和加拿大开展的多中心研究，旨在评估罗培法新干扰素α-2b-njft治疗原发性血小板增多症患者的疗效、安全性和耐受性：EXCEED-ET试验。
Front Med (Lausanne). 2025 Apr 17;12:1548590. doi: 10.3389/fmed.2025.1548590. eCollection 2025.
4
Population Pharmacokinetics-Pharmacodynamics and Exposure-Response of Ropeginterferon Alfa-2b in Chinese and Japanese Patients With Polycythemia Vera.聚乙二醇干扰素α-2b在中国和日本真性红细胞增多症患者中的群体药代动力学-药效学及暴露-反应关系
Pharmacol Res Perspect. 2025 Jun;13(3):e70109. doi: 10.1002/prp2.70109.
5
The higher initial dose and accelerated titration regimen of ropeginterferon as a treatment option for certain patients with polycythaemia vera.聚乙二醇干扰素的较高初始剂量和加速滴定方案作为真性红细胞增多症某些患者的一种治疗选择。
Br J Haematol. 2025 Mar;206(3):986-987. doi: 10.1111/bjh.19998. Epub 2025 Jan 12.
聚乙二醇干扰素α-2b治疗真性红细胞增多症患者的暴露-疗效和暴露-安全性分析。
Br J Clin Pharmacol. 2024 Jun;90(6):1493-1502. doi: 10.1111/bcp.16043. Epub 2024 Mar 19.
4
A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera.聚乙二醇干扰素α-2b的一种新给药方案高效且耐受性良好：一项针对中国真性红细胞增多症患者的2期研究结果
Exp Hematol Oncol. 2023 Jun 21;12(1):55. doi: 10.1186/s40164-023-00415-0.
5
A phase II trial to assess the efficacy and safety of ropeginterferon α-2b in Chinese patients with polycythemia vera.一项评估罗特西普干扰素α-2b 在中国真性红细胞增多症患者中的疗效和安全性的 II 期临床试验。
Future Oncol. 2023 Apr;19(11):753-761. doi: 10.2217/fon-2022-1141. Epub 2023 May 2.
6
An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: An overview of previous and ongoing studies with perspectives on the future.聚乙二醇干扰素α-2b的一种替代给药策略可能有助于改善骨髓增殖性肿瘤的治疗结果：既往及正在进行的研究概述与未来展望
Front Oncol. 2023 Jan 19;13:1109866. doi: 10.3389/fonc.2023.1109866. eCollection 2023.
7
JAK2 V617F allele burden in polycythemia vera: burden of proof.真性红细胞增多症中 JAK2 V617F 等位基因负担：证据负担。
Blood. 2023 Apr 20;141(16):1934-1942. doi: 10.1182/blood.2022017697.
8
Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study.罗特西普干扰素α-2b 在日本真性红细胞增多症患者中的疗效和安全性：一项开放标签、单臂、2 期研究。
Int J Hematol. 2022 Aug;116(2):215-227. doi: 10.1007/s12185-022-03341-9. Epub 2022 Apr 16.
9
Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b.接受罗培戈干扰素α-2b治疗的真性红细胞增多症患者的长期预后。
Leukemia. 2022 May;36(5):1408-1411. doi: 10.1038/s41375-022-01528-x. Epub 2022 Feb 24.
10
Polycythemia vera: historical oversights, diagnostic details, and therapeutic views.真性红细胞增多症：历史的忽视、诊断的细节和治疗的观点。
Leukemia. 2021 Dec;35(12):3339-3351. doi: 10.1038/s41375-021-01401-3. Epub 2021 Sep 3.